Tag: CIRSE
Five-year RCT data provide upbeat message on Luminor paclitaxel-coated balloon’s safety...
NOTE: This video is ONLY available to watch in selected countries and geographies
The EffPac trial was a prospective, multicentre, randomised controlled trial (RCT)...
CIRSE supports use of paclitaxel-coated devices in femoropopliteal disease treatment
In June 2023, the Cardiovascular Interventional Radiological Society of Europe (CIRSE) published an editorial in Cardiovascular Interventional Radiology (CVIR). Written on behalf of CIRSE’s...
Real-world data consistent with RCTs in highlighting the efficacy of drug-eluting...
This advertorial is sponsored by Boston Scientific.
During a recent satellite symposium, which took place at the 2022 Cardiovascular Interventional Radiological Society of Europe (CIRSE)...
Aperto® drug-coated balloon technology shows promise in dialysis access patients
This advertorial is sponsored by Cardionovum®.
The Aperto drug-coated balloon (DCB) technology (Cardionovum) is “one of the very promising new technologies” for treating central vein stenosis...
SAVAL trial finds no gains with custom drug-eluting stents in PAD...
Day one of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2022 annual meeting (10–14 September, Barcelona, Spain) put a strong focus on...
“Very encouraging” 12-month data from WRAPSODY FIRST study presented at CIRSE...
Twelve-month results from a first-in-human study of the Wrapsody cell-impermeable endoprosthesis (Merit Medical Systems) for the treatment of access circuit stenosis in haemodialysis patients...
Reaction to the Katsanos et al meta-analysis
Internal BIBA MedTech data show that perceptions on paclitaxel devices have shifted considerably in the twelve months that have elapsed since Konstantinos Katsanos (Patras,...
Experts discuss latest results from EFFPAC and TINTIN trials presented at...
NOTE: ONLY intended for healthcare professionals outside of the USA.
Ulf Teichgräber (Jena, Germany) and Koen Deloose (Dendermonde, Belgium) discuss the 24-month results of the...
CIRSE updates position on paclitaxel use in peripheral arteries
The Cardiovascular and Interventional Radiological Society of Europe (CIRSE) has released a statement on the use of paclitaxel-coated balloons and stents in the treatment...
Eluvia outperforms Zilver PTX in IMPERIAL 12-month results
The Eluvia drug-eluting vascular stent system (Boston Scientific) shows superior primary patency compared to the Zilver PTX drug-eluting stent (Cook Medical), concludes the 12-month...
Luminor drug-coated balloon receives Canadian Medical Device Licence
iVascular has announced that its Luminor 14m peripheral balloon catheter with paclitaxel elution has received the Canadian Medical Device Licence (MDL).
Luminor 14m is a...
Data from multiple studies support concept of low metal burden therapies...
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce restenosis rates, according to results from various Biotronik studies...
Luminor EffPAC study shows efficacy at six months
Data have been announced demonstrating the efficacy of iVascular’s Luminor drug-coated balloon (DCB) in patients with peripheral artery disease (PAD) at six months. The...
Eluvia paclitaxel-eluting vascular stent system demonstrates promising three-year freedom from revascularisation
The three-year results from the MAJESTIC trial for Boston Scientific’s Eluvia paclitaxel-eluting vascular stent system at the Cardiovascular and Interventional Radiological Society of Europe...
Two-year MAJESTIC data show sustained positive results for Eluvia drug-eluting stent
The MAJESTIC trial set out to evaluate the performance of the Eluvia paclitaxel-eluting vascular stent system (Boston Scientific) in the treatment of femoropopliteal artery...
